Alder’s Clazakizumab Yields Promising Results for Rheumatoid Arthritis Treatment in Phase 2 Trial
News, rheumatoid arthritis
Alder BioPharmaceuticals, Inc. recently announced that its therapeutic antibody clazakizumab (ALD518) has met the primary endpoint of a Phase 2b clinical trial in adult patients with rheumatoid arthritis (RA). The results ... Read more